A protective role of a cholesteryl ester transfer protein gene variant towards ischaemic stroke in Sardinians

Journal of Internal Medicine

Volumn 262, Issue 5, 2007, Pages 555-561

  Quarta, G ^b   Stanzione, R ^c   Evangelista, A ^c   Zanda, B ^d   Sciarretta, S ^b   Di Angelantonio, E ^a   Marchitti, S ^c   Di Murro, D ^c   Volpe, M ^b,c   Rubattu, S ^a,b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cholesteryl ester transfer protein; Genetics; Ischaemic stroke; Polymorphism; Taq1 B

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENDER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GROUPS BY AGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROPROTECTION; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECESSIVE INHERITANCE; STATISTICAL SIGNIFICANCE;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS; SEX DISTRIBUTION; STROKE;

EID: 35448982326     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01845.x     Document Type: Article

References (36)

1. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation 2004 110 : 1868 73.
2. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: part II: clinical implications. Circulation 2004 110 : 2066 71.
3. Goldschmidt-Clermont PJ, Creager MA, Losordo DW, Lam GK, Wassef M, Dzau VJ. Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation 2005 112 : 3348 53.
4. Rosamond W, Flegal K, Friday G et al. Heart Disease and Stroke Statistics-2007 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 115 : e69 171.
5. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 62 : 707 14.
6. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996 124 : S11 20.
7. Asztalos BF, Schaefer EJ. HDL in atherosclerosis: actor or bystander? Atheroscler Suppl 2003 4 : 21 9.
8. Barter PJ, Brewer HB Jr., Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003 23 : 160 7.
9. Shah PK. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J 2007 28 : 5 12.
10. Ordovas JM, Cupples LA, Corella D et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000 20 : 1323 9.
11. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation 2000 102 : 2197 203.
12. Pallaud C, Sass C, Zannad F, Siest G, Visvikis S. APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort). Clin Genet 2001 59 : 316 24.
13. Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V. The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis 2001 159 : 187 92.
14. Liu S, Schmitz C, Stampfer MJ et al. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 2002 161 : 469 74.
15. Brousseau ME, O'Connor JJ Jr., Ordovas JM et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002 22 : 1148 54.
16. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998 338 : 86 93.
17. Elosua R, Cupples LA, Fox CS et al. Association between well-characterized lipoprotein-related genetic variants and carotid intimal medial thickness and stenosis: The Framingham Heart Study. Atherosclerosis 2006 189 : 222 8.
18. Meguro S, Takei I, Murata M et al. Cholesteryl ester transfer protein polymorphism associated with macroangiopathy in Japanese patients with type 2 diabetes. Atherosclerosis 2001 156 : 151 6.
19. Asselbergs FW, Moore JH, van den Berg MP et al. A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study. BMC Med Genet 2006 7 : 39.
20. Fidani L, Hatzitolios AI, Goulas A, Savopoulos C, Basayannis C, Kotsis A. Cholesteryl ester transfer protein TaqI B and lipoprotein lipase Ser447Ter gene polymorphisms are not associated with ischaemic stroke in Greek patients. Neurosci Lett 2005 384 : 102 5.
21. Rubattu S, Stanzione R, Di Angelantonio E et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004 35 : 814 8.
22. Zee RY, Fernandez-Otiz A, Macaya C, Pinter E, Lindpaintner K, Fernandez-Cruz A. Lipid metabolism and occurrence of post-percutaneous transluminal coronary angioplasty restenosis: role of cholesteryl ester transfer protein and paraoxonase/arylesterase. J Thromb Haemost 2003 1 : 1202 7.
23. Mickey R, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989 129 : 125 37.
24. Kuivenhoven JA, de Knijff P, Boer JM et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997 17 : 560 8.
25. Zhuang Y, Wang J, Qiang H et al. Serum cholesteryl ester transfer protein concentrations in healthy Chinese subjects and cardio-cerebrovascular disease patients. Clin Chim Acta 2001 305 : 19 25.
26. Rittershaus CW, Miller DP, Thomas LJ et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000 20 : 2106 12.
27. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003 169 : 113 20.
28. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000 406 : 203 7.
29. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002 105 : 2159 65.
30. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006 48 : 1774 81.
31. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006 48 : 1782 90.
32. Boekholdt SM, Sacks FM, Jukema JW et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005 111 : 278 87.
33. Kauma H, Savolainen MJ, Heikkila R et al. Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors. Hum Genet 1996 97 : 156 62.
34. Siniscalco M, Robledo R, Bender PK, Carcassi C, Contu L, Beck JC. Population genomics in Sardinia: a novel approach to hunt for genomic combination underlying complex trait and disease. Cytogenet Cell Genet 1999 86 : 148 52.
35. Lampis R, Morelli L, Congia M et al. The interegional distribution of HLA class II haplotypes indicates the suitability of the Sardinian population for case-control association studies in complex disease. Human Mol Genet 2000 9 : 2959 65.
36. Rubattu S, Di Angelantonio E, Nitsch D et al. Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Thromb Haemost 2005 93 : 1095 100.